Every material Form 8-K Illumina filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Illumina announced third-quarter 2026 financial results with reported revenue of $1.13 billion, representing a 4.2% increase compared to the prior-year period. Driven by healthy clinical demand and NovaSeq X placements, the company raised its full-year 2026 total revenue guidance to $4.64-$4.66 billion and non-GAAP diluted EPS guidance to $5.40-$5.45.
Reported revenue for Q3 2026 was $1.13 billion, up 4.2% from Q3 2025.
GAAP diluted EPS for Q3 2026 was $1.43, compared to $0.98 in Q3 2025.
Free cash flow for Q3 2026 reached $378 million, compared to $253 million in the prior-year period.
Full-year 2026 revenue guidance was raised to $4.64-$4.66 billion, up from the previous range.
Illumina entered into dealer agreements on October 8, 2026, to establish an unsecured commercial paper program allowing short-term notes of up to $1.0 billion outstanding at any time. The company said no notes were outstanding as of the filing date and proceeds are expected to fund general corporate purposes, so the program adds borrowing capacity rather than existing debt.
Program caps outstanding CP Notes at $1.0 billion; no notes were outstanding as of the filing date
Maturities may not exceed 397 days from the date of issue
Three commercial paper dealers and a national bank as issuing and paying agent
Proceeds expected for general corporate purposes; dealer agreement form filed as Exhibit 10.1
On August 13, 2026, Illumina entered into a new $1,000 million senior unsecured five-year revolving credit facility with Bank of America, N.A. as administrative agent, which replaces the Existing Credit Agreement dated January 4, 2023, that was terminated the same day. As of the filing date, no borrowings were outstanding, and the facility matures on August 13, 2031, subject to extension options.
Facility size: $1,000 million senior unsecured five-year revolving credit, with a $50 million swingline sublimit and a $75 million letter of credit sublimit
Option to add up to $500 million in term loans or commitment increases, subject to lender consent
No borrowings outstanding as of the filing date; maturity August 13, 2031
Existing Credit Agreement dated January 4, 2023 was terminated as of August 13, 2026
Illumina reported second-quarter 2026 revenue of $1.16 billion, up 9.5% from a year earlier, and non-GAAP diluted EPS of $1.31, up from $1.19. GAAP diluted EPS fell to $1.35 from $1.49, and the company raised its fiscal 2026 revenue and non-GAAP EPS guidance. For shareholders, the higher outlook is the key development, though GAAP earnings declined year over year.
Q2 2026 revenue was $1.16 billion, up 9.5% from Q2 2025; non-GAAP diluted EPS was $1.31 versus $1.19, while GAAP diluted EPS was $1.35 versus $1.49
Fiscal 2026 total revenue guidance raised to $4.60-$4.64 billion from $4.52-$4.62 billion
Fiscal 2026 non-GAAP diluted EPS guidance raised to $5.30-$5.40 from $5.15-$5.30; non-GAAP operating margin guidance unchanged at 23.4%-23.6%
Free cash flow was $162 million for Q2 2026, compared with $204 million a year earlier
Illumina expanded its board from nine to ten members on June 16, 2026, and appointed Daniel M. Skovronsky, M.D., Ph.D., effective immediately. Dr. Skovronsky is Chief Scientific and Product Officer of Eli Lilly and Company, and the filing says he qualifies as an independent director under Nasdaq and SEC rules. The filing describes this as a board governance change and does not report any financial results or guidance.
Board size increased from nine to ten members; Dr. Skovronsky appointed effective June 16, 2026
Dr. Skovronsky will stand for election at the 2027 annual meeting for a one-year term
Filing states he is independent under Nasdaq and SEC rules and has no related-party transactions reportable under Item 404(a)
He will participate in the non-employee director compensation programs described in the April 9, 2026 proxy statement
Illumina reported first-quarter 2026 revenue of $1.09 billion, up 4.8% from a year earlier, and non-GAAP diluted EPS of $1.15 versus $0.97. The company raised its fiscal 2026 non-GAAP EPS guidance and its board authorized a new $1.5 billion share repurchase program, which adds to remaining capacity under the 2024 program.
Q1 2026 revenue $1.09 billion, up 4.8% from Q1 2025; GAAP diluted EPS $0.87 versus $0.82
Non-GAAP diluted EPS $1.15 versus $0.97 in Q1 2025; GAAP net income $134 million versus $131 million
FY2026 non-GAAP diluted EPS guidance raised to $5.15-$5.30 from $5.05-$5.20; revenue guidance raised $20 million at the midpoint to $4.52-$4.62 billion
Board authorized up to $1.5 billion in new buybacks on April 28, 2026; about $314 million remained under the August 2024 program as of April 29, 2026
Illumina said three directors, Frances Arnold, Robert S. Epstein and Gary S. Guthart, will retire from its Board effective May 21, 2026, the date of the 2026 annual meeting. The company said the retirements are not the result of any disagreement with the company or the Board, and the Board has nominated David P. King for election at that meeting. The filing does not include financial results or guidance, so the change is a governance matter for shareholders to weigh.
Drs. Frances Arnold, Robert S. Epstein and Gary S. Guthart intend to retire as directors effective May 21, 2026
The filing states the retirements are not due to any dispute or disagreement with the company or Board
The Board has nominated David P. King for election as a director at the 2026 annual meeting
King is the former Executive Chairman and CEO of Laboratory Corporation of America Holdings
Illumina reported fourth-quarter 2025 revenue of $1.16 billion, up 5% from a year earlier, and fiscal 2025 revenue of $4.34 billion, flat versus 2024. GAAP net income for fiscal 2025 was $850 million, compared with a net loss of $1.22 billion in 2024 that included impairment charges, and non-GAAP diluted EPS was $4.84 versus $4.16. For fiscal 2026 the company expects revenue of $4.5 billion to $4.6 billion and non-GAAP diluted EPS of $5.05 to $5.20, including $0.18 of dilution from the SomaLogic acquisition.
Q4 2025 non-GAAP diluted EPS was $1.35, versus $0.95 in Q4 2024; Q4 2025 GAAP operating margin was 17.4%.
Fiscal 2025 ex-China revenue was $4.10 billion, up 2% from 2024; free cash flow was $931 million.
Fiscal 2026 guidance includes ex-China organic revenue growth of 2% to 4% and a non-GAAP operating margin of 23.3% to 23.5%.
Illumina completed its acquisition of SomaLogic and related aptamer-based and functional proteomics assets from Standard BioTools on January 30, 2026, paying $350 million in cash at closing, subject to customary adjustments. The deal adds up to $75 million in potential milestone payments and royalties tied to product and service revenue, and Illumina said it funded the purchase with cash on hand. The filing does not give financial results for the acquired business, which Illumina said it will discuss on its February 5, 2026 earnings call.
Purchase price of $350 million in cash at closing, subject to customary adjustments
Up to $75 million in potential milestone payments to Standard BioTools, plus royalty streams
Transaction completed January 30, 2026; agreement dated June 22, 2025
Illumina will discuss the financial implications on its February 5, 2026 earnings call
Illumina released unaudited preliminary results for the fourth quarter and fiscal year 2025 ahead of a J.P. Morgan Healthcare Conference webcast on January 13, 2026. Fourth-quarter revenue rose 5% to about $1.155 billion, while full-year revenue was flat at about $4.34 billion. The company said the figures are subject to audit and adjustment, and full results are due February 5, 2026.
Q4 2025 revenue of about $1.155 billion, up 5% from Q4 2024 (up 4% on a constant currency basis)
Q4 2025 ex-China revenue of about $1.100 billion, up 7% from Q4 2024
Preliminary GAAP diluted EPS of $2.14 to $2.17 for Q4 and $5.42 to $5.45 for fiscal 2025; non-GAAP diluted EPS of $1.27 to $1.30 for Q4 and $4.76 to $4.79 for fiscal 2025
Full fourth-quarter and fiscal 2025 results are scheduled after market close on February 5, 2026
Illumina said it appointed Eric D. Green, M.D., Ph.D., former director of the National Human Genome Research Institute, as Chief Medical Officer effective February 2, 2026. Chief Commercial Officer Everett Cunningham is resigning effective January 16, 2026, and CEO Jacob Thaysen will serve as interim chief commercial officer until a successor is named.
Eric D. Green, M.D., Ph.D., appointed Chief Medical Officer, effective February 2, 2026; reports to the CEO
Green served as NHGRI Director from 2009 to 2025 and spent more than three decades at the National Institutes of Health
Everett Cunningham resigns as Chief Commercial Officer effective January 16, 2026; he has been appointed CEO of a life science tools company
CEO Jacob Thaysen will act as interim chief commercial officer until a permanent successor is named
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Illumina filing is on SEC EDGAR ↗. 8-K briefs of other companies →